Medications given for HF may affect zinc metabolism in different ways. It was shown that thiazides may cause zincuria and a decrease in tissue zinc concentration. There is conflicting evidence about furosemide, even though patients with chronic furosemide treatment showed low tissue zinc levels in ...
Anti-obesity medication (AOM) semaglutide has been shown to be efficacious at both causing intentional weight loss and improving HF symptom burden, with some evidence to suggest that HF clinical events may also be reduced. Additional ongoing trials of AOM in patients with cardiovascular disease, ...
Main Outcomes and Measures The outcomes of interest were the composite of CV death or hospitalization for HF (HHF), HHF alone, and a kidney-specific composite outcome (persistent ≥40% decrease in estimated glomerular filtration rate [eGFR], end-stage kidney disease, or kidney-related death). ...
Neither amlodipine nor felodipine increases cardiovascular morbidity or mortality in patients with HF.30,31 However, neither have they demonstrated benefit when compared with placebo in this patient population. Studies have not clearly determined their role in HF. Hence, these 2 CCBs will not be addr...
The goals of glaucoma therapy for the patient and the physician are ultimately the same ones, but they are often approached from very different perspectives. Most patients with glaucoma visit their ophthalmologist on a regular basis because they understa
an increase of 10% in the average percentage optimal dose was associated with a reduction in 180-day HF readmission or all-cause death (primary end point: adjusted hazard ratio [aHR], 0.89; 95% CI, 0.81-0.98; P = .01) and a decrease in 180-day all-cause mortality (aHR, 0.84;...
Other studies have demonstrated varied responses depending on the treatment duration and drug type. For example, Sardu et al. [24] found that treatment with GLP-1 RA over 12 months resulted in improvements in all measured cardiac dimensions, alongside a decrease in arrhythmic events and heart fa...